# Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

> **NCT03237988** · PHASE1 · COMPLETED · sponsor: **Corvus Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** CPI-444 Capsules
- **DRUG:** CPI-444 Tablets

## Key facts

- **NCT ID:** NCT03237988
- **Lead sponsor:** Corvus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-20
- **Primary completion:** 2017-09-20
- **Final completion:** 2017-10-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03237988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03237988, "Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03237988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*